Studies have shown that active fund managers routinely underperform the S&P500 index*​

MiNK Therapeutics, Inc. (NASDAQ: INKT)

INKT Stock Predictions and Ratings

WSX Rating:
NOT AVAILABLE
WSX Forecast (1yr):
NOT AVAILABLE
Analyst Rating:
BUY
Analyst Forecast (1yr):
37.10%

INKT Stock Analysis

INKT PE Ratio:

INKT PEG Ratio: Not Available

INKT Forward EPS Growth (12 month): 0.00%

INKT PS Ratio:

INKT PSG Ratio: Not Available

INKT Forward Revenue Growth (12 month): 0.00%

INKT Articles

No data was found